Overview

Study of Daclizumab in Patients With Chronic, Persistent Asthma

Status:
Completed
Trial end date:
2003-12-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to evaluate an investigational medication to treat chronic persistent asthma. The research is being conducted at up to 22 clinical research sites in the US and is open to both men and women ages 18 to 70 years old. Participants in the study will have a number of visits to a research site over a 10-month period. All study-related care and medication is provided to qualified participants at no cost: this includes all visits, examinations and laboratory work.
Phase:
Phase 2
Details
Lead Sponsor:
Facet Biotech
Treatments:
Daclizumab
Immunoglobulin G